North Star Asset Management’s Pacira BioSciences PCRX Stock Holding History

North Star Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,400	Closed	-$239K	–	248
2016 Q4	$239K	Hold	7,400	–	–	0.03%	215
2016 Q3	$253K	Hold	7,400	–	–	0.03%	208
2016 Q2	$250K	Hold	7,400	–	–	0.03%	210
2016 Q1	$392K	Hold	7,400	–	–	0.05%	183
2015 Q4	$568K	Hold	7,400	–	–	0.07%	168
2015 Q3	$304K	Hold	7,400	–	–	0.04%	198
2015 Q2	$523K	Buy	7,400 +2,300	+45%	+$181K	0.06%	179
2015 Q1	$453K	Sell	5,100 -2,200	-30%	-$223K	0.05%	187
2014 Q4	$647K	Hold	7,300	–	–	0.07%	166
2014 Q3	$708K	Buy	7,300 +2,300	+46%	+$224K	0.08%	160
2014 Q2	$459K	Hold	5,000	–	–	0.05%	186
2014 Q1	$350K	Buy	+5,000	New	+$340K	0.04%	194

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Westfield Capital Management

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return